• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Global Biotechnology Market Expected to Undergo a Number of Transformations
 

Global Biotechnology Market Expected to Undergo a Number of Transformations

on

  • 388 views

The global biotechnology market is expected to undergo a number of transformations. These include a shift of growth from the developed to the emerging markets, an increasing focus on monoclonal ...

The global biotechnology market is expected to undergo a number of transformations. These include a shift of growth from the developed to the emerging markets, an increasing focus on monoclonal antibodies and an increasing penetration of biosimilars/follow-on-biologics.

Statistics

Views

Total Views
388
Views on SlideShare
388
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Microsoft Word

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Global Biotechnology Market Expected to Undergo a Number of Transformations Global Biotechnology Market Expected to Undergo a Number of Transformations Document Transcript

    • Global Biotechnology Market Expected to Undergo a Number ofTransformationsThe global biotechnology market is expected to undergo a number of transformations. Theseinclude a shift of growth from the developed to the emerging markets, an increasing focus onmonoclonal antibodies and an increasing penetration of biosimilars/follow-on-biologics.The global biotechnology market is expected to grow at a CAGR of 7% during 2013-2017reaching sales worth nearly US$ 166 billion by 2017. This market, however, is expected toundergo a number of transformations which would impact the course of its growth. Thesetransitions include a shift of growth from the developed to the emerging markets, anincreasing focus on monoclonal antibodies compared to therapeutic proteins and anincreasing penetration of biosimilars/follow-on-biologics compared to their branded versions.As a result of these transformations, the need for a user friendly, robust and comprehensivebiotechnology market intelligence has become imperative for investors, researchers,consultants, marketing strategists, and all those who are planning to foray into thebiotechnology market in some form or the other.IMARC Group, one of the world’s leading research and advisory firms, introduces a new andrevolutionary way to understand and evaluate the global biotechnology market with its newreport entitled “Global Biopharmaceutical Market Report & Forecast: 2012-2017”. Thisreport provides an analytical and statistical insight into the global biotechnology market. Thestudy, which has been undertaken using desk based as well as primary market research is amust for: pharmaceutical manufacturers, biopharmaceutical manufacturers, drug deliverydevice manufacturers, PE firms, FDI investors, planning agencies, consultants, researchfirms, credit rating agencies, etc.Regions/Countries Covered:North America: United States and CanadaLatin America: Mexico, Brazil and ArgentinaEurope: Germany, France, Italy, Spain, United Kingdom, Russia and TurkeyAsia Pacific: Japan, China, Australia, South Korea, India and IndonesiaTable of Contents1. Market Definitions & Research Methodology2. Analyst Briefing
    • 3. Introduction to Biopharmaceuticals4. Global Biopharmaceutical Market: Industry Analysis4.1 Strengths4.1.1 High Efficacy and Target Oriented Attack4.1.2 Strong Potential to Achieve Blockbuster Status4.1.3 Limited Generic Threat4.1.4 Approval Success Rates are Higher than Small Molecule Drugs4.2 Weaknesses4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives4.2.2 Second Line of Therapy4.2.3 Huge Cost of Therapy4.2.4 High Incidence of Unfavorable Side Effects4.3 Opportunities4.3.1 Diseases with High Unmet Needs4.3.2 Expanding the Patient Pool by Approval into Additional Indications4.3.3 Emerging Markets4.3.4 Increasing New Approvals and a Strong Pipeline4.4 Threats4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture4.4.2 Biosimilars4.4.3 Limited and Conditional Reimbursement4.4.4 Uncertainties in the Economic Environment5. Global Biopharmaceutical Market: Industry Performance5.1 Market Performance & Forecast5.1.1 Current Performance (2005-2011)5.1.2 Market Forecast (2012-2017)5.2 Market Segmentation by Region5.2.1 Current Performance (2005-2011)5.2.2 Market Forecast (2012-2017)5.3 Market Segmentation by Indication5.4 Market Segmentation by Class5.4.1 Recombinant Proteins5.4.1.1 Current Performance (2005-2011)5.4.1.2 Market Forecast (2012-2017)5.4.2 Monoclonal Antibodies5.4.2.1 Current Performance (2005-2011)5.4.2.2 Market Forecast (2012-2017)
    • 5.4.3 Purified Proteins5.4.3.1 Current Performance (2005-2011)5.4.3.2 Market Forecast (2012-2017)5.5 Competitive Landscape5.5.1 Top Biopharmaceutical Players5.5.2 Top Biopharmaceutical Drugs6. North America6.1 US6.1.1 Market Performance (2005-2011)6.1.2 Market Segmentation by Class6.1.2.1 Recombinant Proteins6.1.2.2 Monoclonal Antibodies6.1.2.3 Purified Proteins6.1.3 Performance of Top Players6.1.4 Market Forecast (2012-2017)6.2 Canada6.2.1 Market Performance (2005-2011)6.2.2 Market Segmentation by Class6.2.2.1 Recombinant Proteins6.2.2.2 Monoclonal Antibodies6.2.3 Performance of Top Players6.2.4 Market Forecast (2012-2017)7. Latin America7.1 Mexico7.1.1 Market Performance (2005-2011)7.1.2 Market Segmentation by Class7.1.2.1 Recombinant Proteins7.1.2.2 Monoclonal Antibodies7.1.2.3 Purified Proteins7.1.3 Performance of Top Players7.1.4 Market Forecast (2012-2017)7.2 Brazil7.2.1 Market Performance (2005-2011)7.2.2 Market Segmentation by Class7.2.2.1 Recombinant Proteins7.2.2.2 Monoclonal Antibodies7.2.2.3 Purified Proteins
    • 7.2.3 Performance of Top Players7.2.4 Market Forecast (2012-2017)7.3 Argentina7.3.1 Market Performance (2005-2011)7.3.2 Market Segmentation by Class7.3.2.1 Recombinant Proteins7.3.2.2 Monoclonal Antibodies7.3.2.3 Purified Proteins7.3.3 Performance of Top Players7.3.4 Market Forecast (2012-2017)8. Europe8.1 Germany8.1.1 Market Performance (2005-2011)8.1.2 Market Segmentation by Class8.1.2.1 Recombinant Proteins8.1.2.2 Monoclonal Antibodies8.1.2.3 Purified Proteins8.1.3 Performance of Top Players8.1.4 Market Forecast (2012-2017)8.2 France8.2.1 Market Performance (2005-2011)8.2.2 Market Segmentation by Class8.2.2.1 Recombinant Proteins8.2.2.2 Monoclonal Antibodies8.2.2.3 Purified Proteins8.2.3 Performance of Top Players8.2.4 Market Forecast (2012-2017)8.3 Italy8.3.1 Market Performance (2005-2011)8.3.2 Market Segmentation by Class8.3.2.1 Recombinant Proteins8.3.2.2 Monoclonal Antibodies8.3.2.3 Purified Proteins8.3.3 Performance of Top Players8.3.4 Market Forecast (2012-2017)8.4 Spain8.4.1 Market Performance (2005-2011)
    • 8.4.2 Market Segmentation by Class8.4.2.1 Recombinant Proteins8.4.2.2 Monoclonal Antibodies8.4.2.3 Purified Proteins8.4.3 Performance of Top Players8.4.4 Market Forecast (2012-2017)8.5 UK8.5.1 Market Performance (2005-2011)8.5.2 Market Segmentation by Class8.5.2.1 Recombinant Proteins8.5.2.2 Monoclonal Antibodies8.5.2.3 Purified Proteins8.5.3 Performance of Top Players8.5.4 Market Forecast (2012-2017)8.6 Russia8.6.1 Market Performance (2005-2011)8.6.2 Market Segmentation by Class8.6.2.1 Recombinant Proteins8.6.2.2 Monoclonal Antibodies8.6.2.3 Purified Proteins8.6.3 Performance of Top Players8.6.4 Market Forecast (2012-2017)8.7 Turkey8.7.1 Market Performance (2005-2011)8.7.2 Market Segmentation by Class8.7.2.1 Recombinant Proteins8.7.2.2 Monoclonal Antibodies8.7.2.3 Purified Proteins8.7.3 Performance of Top Players8.7.4 Market Forecast (2012-2017)9. Asia Pacific9.1 Japan9.1.1 Market Performance (2005-2011)9.1.2 Market Segmentation by Class9.1.2.1 Recombinant Proteins9.1.2.2 Monoclonal Antibodies9.1.2.3 Purified Proteins
    • 9.1.3 Performance of Top Players9.1.4 Market Forecast (2012-2017)9.2 China9.2.1 Market Performance (2005-2011)9.2.2 Market Segmentation by Class9.2.2.1 Recombinant Proteins9.2.2.2 Monoclonal Antibodies9.2.2.3 Purified Proteins9.2.3 Performance of Top Players9.2.4 Market Forecast (2012-2017)9.3 Australia9.3.1 Market Performance (2005-2011)9.3.2 Market Segmentation by Class9.3.2.1 Recombinant Proteins9.3.2.2 Monoclonal Antibodies9.3.2.3 Purified Proteins9.3.3 Performance of Top Players9.3.4 Market Forecast (2012-2017)9.4 South Korea9.4.1 Market Performance (2005-2011)9.4.2 Market Segmentation by Class9.4.2.1 Recombinant Proteins9.4.2.2 Monoclonal Antibodies9.4.2.3 Purified Proteins9.4.3 Performance of Top Players9.4.4 Market Forecast (2012-2017)9.5 India9.5.1 Market Performance (2005-2011)9.5.2 Market Segmentation by Class9.5.2.1 Recombinant Proteins9.5.2.2 Monoclonal Antibodies9.5.2.3 Purified Proteins9.5.3 Performance of Top Players9.5.4 Market Forecast (2012-2017)9.6 Indonesia9.6.1 Market Performance (2005-2011)9.6.2 Market Segmentation by Class
    • 9.6.2.1 Recombinant Proteins9.6.2.2 Monoclonal Antibodies9.6.3 Performance of Top Players9.6.4 Market Forecast (2012-2017)To buy the complete report or to get a free sample, please contact:IMARC Group AsiaEmail: apac@imarcgroup.comPhone: +91-120-415-5099IMARC Group North AmericaEmail: america@imarcgroup.comPhone: +1-631-791-1145IMARC Group Europe, Middle East & AfricaEmail:ema@imarcgroup.comPhone: +44-702-409-7331To know more please visit: http://www.imarcgroup.com/global-biopharmaceutica-market-report-forecasts-2012-2017/